Helloworld: Get ready to say “Hello World”

About the author:

Belinda Moore
Author name:
By Belinda Moore
Job title:
Senior Analyst
Date posted:
22 February 2022, 10:30 AM
Sectors Covered:
Agriculture, Food & Beverage, Travel and Chemicals

  • The 1H22 continued to be a challenging period for Helloworld (ASX:HLO) given COVID-related travel restrictions and materially less government support. However, the result was better than we expected. Tight cost control saw HLO keep losses to a minimum.
  • 2H22 outlook comments were stronger than expected with a breakeven or better outcome in the 4Q22. With domestic and international borders reopened or about to reopen, HLO was upbeat about the pent-up demand for travel.
  • Backing out its investment in CTD from its EV, HLO is materially undervalued, trading on a recovery year EV/EBITDA multiple of only 4.0x. Add maintained.

Event: 1H22 result beats expectations

In 1H22 TTV rose 60.4% to A$694.3m (1Q A$266.5m, 2Q A$427.8m), travel-related revenue increased 45.2% to A$40.3m and HLO reported an EBITDA loss of A$5.2m (1Q A$3.6m, 2Q A$1.6m). TTV and EBITDA beat our forecast.

Analysis: materially higher TTV but less Gov support = flattish EBITDA

The 1H22 was a credible outcome considering travel restrictions and there was materially less government support during this period. TTV was approx. 22% of pre-COVID levels over the half. HLO maintained strict cost control. The result also benefited from Corporate being profitable over the 1H.

Monthly operating cash outflows were ~A$1.5m; however, due to a reduction in client cash (refunds and supplier payments), timing of overhead payments and payment of employee entitlements, the operating cash outflow was materially worse than expected at A$26.1m (vs. A$8.9m in the pcp and MorgansF -A$7.5m).

HLO ended 1H22 with modest net debt of A$1.0m.

Outlook is improving with borders reopening

No formal FY22 earnings guidance was provided. However, HLO did say that the business will incur cash losses of A$1.0-1.5m per month over the 3Q22 and in the 4Q22 it intends to break even or be slightly (EBITDA) profitable.

HLO has guided to modest profitability in FY23 and believes it can return to FY19 levels of EBITDA excluding corporate (~A$55m) in FY24-25, with potential upside from the efficiency benefits of its new technology and structural costs out.

HLO expects domestic and international travel to return rapidly with the opening of the ANZ borders as well as the WA state border. The business has received many enquiries and bookings already (both inbound and outbound). Specifically, HLO has significant forward (international) bookings for the latter part of CY22 and throughout CY23. Most domestic bookings are for the next 3-6 months.

It noted that consumers are cashed up and spending more on travel. As demand returns, there is already strong demand to use an agent as travel is complicated due to COVID-related travel restrictions (every country has its own set of rules and regulations).

Additionally, HLO expects to win significant market share given the closure of approximately half the bricks and mortar stores in ANZ. HLO’s agent numbers have proven to be relatively resilient (fell 4.7% to 2,168 in 1H22 vs pcp).

The sale of Corporate is on track for completion in March and will boost its liquidity position by approx. A$175m.

Forecast implications

Given HLO’s stronger-than-expected 2H22 outlook comments, we have reduced our FY22 EBITDA loss to A$9.0m from A$13.5m previously. We forecast HLO’s earnings to recover to proforma FY19 levels (plus cost out) in FY24 (or EBITDA of A$57m).

Investment view

With a strong balance sheet post the sale of Corporate, HLO will be well placed to capitalise on the pent-up demand for Leisure travel and acquisition opportunities. Backing out its CTD shareholding from its EV, HLO is materially undervalued trading on a recovery year (FY24) EV/EBITDA multiple of 4x.

However, it is a late-cycle COVID recovery story given its exposure to inbound and outbound travel to and from ANZ and therefore investors will need to be patient.

Share price catalysts include the completion of the sale of Corporate, increasing international arrivals/departures and accretive acquisitions. The key risk is if new COVID variants continue to emerge, further delaying the travel recovery.

Find out more

Download full research note

You can find further detailed analysis of company results this reporting season by browsing our reporting season tag, and view a full list of upcoming results on our Reporting Season Calendar.

If you would like access or more information, please contact your adviser or nearest Morgans office.

Request a call  Find local branch

Need access to our research?

You are also welcome to start a two-week trial of our online platform, which provides access to detailed market analysis and insights, provided by our award-winning research team

Create trial account 

Disclaimer: The information contained in this report is provided to you by Morgans Financial Limited as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents (“Morgans”) do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so.

  • Print this page
  • Copy Link